Home » SRI International Receives NIAID Contract
SRI International Receives NIAID Contract
SRI International, an independent nonprofit R&D organization, has been awarded a $15.5 million contract by the National Institute of Allergy and Infectious Diseases (NIAID) to help develop drugs and vaccines for HIV and associated infections.
SRI will provide a variety of preclinical services, including toxicology, pharmacology, pharmacokinetics, toxicogenomics and other testing requirements to support submission of investigational new drug applications.
The company also is involved in NIAID programs to develop drugs for other infectious diseases, including a $57 million contract for development of anti-infectives, SRI said.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May